Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Research led by Dr Mariana Borsa at the Kennedy Institute has found that a cellular housekeeping mechanism called autophagy plays a major role in ensuring that T cells generate diverse progenies upon cell division. The findings, published in Nature Cell Biology, could help boost vaccine response in older adults.

T stem cells normally undergo asymmetric cell division (left) whereby one daughter cell becomes a long-lived memory T cell. When autophagy is disrupted, both daughter cells inherit old mitochondria (red) and become effector T-cells.

When killer T cells of our immune system divide, they normally undergo asymmetric cell division (ACD): Each daughter cell inherits different cellular components, which drive the cells toward divergent fates – one cell becomes a short-lived fighter called an effector T cell, the other cell becomes a long-lived memory T cell.

Research by Dr. Mariana Borsa and Prof. Katja Simon, with important contributions from members of several labs at the Kennedy Institute of Rheumatology and other collaborators across Europe, has shown for the first time that cellular autophagy – a 'housekeeping' mechanism by which cells degrade and recycle cell cargo – plays a critical role in this decision process.

'Our study provides the first causal evidence that autophagy plays a central role in ensuring that T cells go through ACD normally. We found that when T stem cells divide, daughter cells inherit different mitochondria, which influences T cell fate decisions,' says Mariana. 'By understanding this process, we can start to think about ways to intervene to preserve the function of immune memory cells as we age.'

Read the full paper in Nature Cell Biology.

Read the News & Views in Nature Cell Biology. 

Find out more about the research on the Max Delbrück Center website.

Similar stories

Could patients with common fractures recover without routine hospital follow-up?

The FASTER study will investigate whether thousands of people with common fractures can recover just as well with good-quality advice and rehabilitation guidance, without the need for routine hospital follow-up appointments.

Could the gut’s nervous system hold new clues to treating Crohn’s disease?

Researchers at the Kennedy Institute are investigating whether the nervous system within the gut could provide a new way to understand and ultimately treat Crohn’s disease.

NDORMS appoints a new Research Professor of Regulatory Innovation to help accelerate the development pipeline of new treatments

Lincoln Tsang has been appointed as the new John Climax Research Professor of Regulatory Innovation – a new role at NDORMS and the University of Oxford that brings global regulatory and legal expertise to our ambitions to transform and improve drug development pathways in order to help deliver safe and effective treatments to patients sooner. He will assume this role effective 2 January 2027.

Look Beyond My Skin: Your Psoriasis Could Help Us Understand Who Develops Psoriatic Arthritis

Adults with psoriasis across Europe are invited to take part in an online study aiming to identify who is at risk of developing psoriatic arthritis.

New PI Marie Pust aims to bring microbiome research closer to patients

We welcome Marie-Madlen Pust, who has joined the Kennedy Institute as a new Principal Investigator. Marie will establish a research group combining computational biology with targeted experimental microbiology to identify microbial drivers of chronic inflammatory disease that can be monitored (diagnostic potential) or modified (therapeutic potential).

Oxford EMCRF starts pioneering engineered nTreg trial for severe autoimmune disease

The Oxford Experimental Medicine Clinical Research Facility (EMCRF) has recruited its first patients into the CHILL trial, an early-phase study of an innovative cell therapy for severe autoimmune disease.